O⁶-benzylguanine and BCNU in multiple myeloma: a phase II trial

By Batts Eric   Maisel Christopher   Kane Donna   Liu Lili   Fu Pingfu   O’Brien Timothy   Remick Scot   Bahlis Nizar   Gerson Stanton  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 3, 2007-08 ,pp. : 415-421

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: A phase 2 trial

By Abou-Jawde Rony   Reed Janice   Kelly Megan   Walker Esteban   Andresen Steven   Baz Rachid   Karam Mary   Hussein Mohamad  

Medical Oncology, Vol. 23, Iss. 2, 2006-06 ,pp. : 263-272

Humana Press, Inc

Access to resources Recommend Favorite

Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients

By  

Current Cancer Therapy Reviews, Vol. 9, Iss. 1, 2013-01 ,pp. : 1-7

Bentham Science Publishers

Access to resources Recommend Favorite

Randomized Phase II Trial of Thalidomide Alone versus Thalidomide Plus Interferon Alpha in Patients with Refractory Multiple Myeloma

By Chiou Tzeon-Jye   Wang Teng-Hsu   Chao Tsu-Yi   Lin Sheng-Fung   Tang Jih-Luh   Chen Tsai-Yun   Chang Ming-Chih   Hsueh Erh-Jung   Chen Po-Min  

Cancer Investigation, Vol. 25, Iss. 3, 2007-04 ,pp. : 140-147

Informa Healthcare

Access to resources Recommend Favorite

A Phase II Double-Blind Randomized Study of the Simultaneous Administration of Recombinant Human Interleukin-6 and Recombinant Human Granulocyte Colony-Stimulating Factor Following Paclitaxel and Carboplatin Chemotherapy in Patients with Advanced Epithelial Ovarian Cancer

By Hochster H.   Speyer J.L.   Mandeli J.P.   Runowicz C.   Wadler S.   Berk G.   Wallach R.   Holland J.F.   for the New York Gynecologic Oncology Group  

Gynecologic Oncology, Vol. 72, Iss. 3, 1999-03 ,pp. : 292-297

Elsevier

Access to resources Recommend Favorite